Abraha Habtemariam mainly focuses on Stereochemistry, Ruthenium, Ligand, Adduct and Pyridine. His Stereochemistry research is multidisciplinary, relying on both Redox, Ethylenediamine and Crystal structure. The concepts of his Ruthenium study are interwoven with issues in Cancer cell, Photochemistry, Molecule and Nucleobase.
His studies deal with areas such as Combinatorial chemistry and Reactivity as well as Ligand. His work deals with themes such as Tripeptide, Dimer, Nuclear magnetic resonance spectroscopy and DNA, which intersect with Adduct. As part of the same scientific family, Abraha Habtemariam usually focuses on Pyridine, concentrating on Hexamethylbenzene and intersecting with Denticity, Nicotinamide, Indane and Substitution reaction.
Abraha Habtemariam mainly investigates Stereochemistry, Ruthenium, Ligand, Medicinal chemistry and Adduct. His work carried out in the field of Stereochemistry brings together such families of science as Chelation, Pyridine and Crystal structure. Abraha Habtemariam has included themes like Denticity, Photochemistry, Hydrolysis, Ethylenediamine and Hexamethylbenzene in his Ruthenium study.
His Ligand study incorporates themes from Reactivity and Metal. His Medicinal chemistry research incorporates elements of Formate, Catalysis, Bipyridine, Transfer hydrogenation and Aqueous solution. His work in Adduct addresses subjects such as Nuclear magnetic resonance spectroscopy, which are connected to disciplines such as Platinum.
His primary scientific interests are in Stereochemistry, Medicinal chemistry, Ligand, Ruthenium and Cancer cell. He integrates Stereochemistry with Cisplatin in his study. His Medicinal chemistry study integrates concerns from other disciplines, such as Denticity, Formate, Adduct, Bipyridine and Aqueous solution.
His Ligand research incorporates themes from Pyridine, Cyclopentadienyl complex, Crystal structure, Metal and Transfer hydrogenation. His research in Ruthenium intersects with topics in Photochemistry, Group 2 organometallic chemistry and Dissociation. His Cancer cell research includes elements of HeLa, Oxidative phosphorylation, Cytotoxicity and Cancer research.
The scientist’s investigation covers issues in Cancer cell, Stereochemistry, Ruthenium, Combinatorial chemistry and Ligand. His biological study spans a wide range of topics, including Apoptosis, Cancer research, Oxaliplatin and Bioinformatics. Abraha Habtemariam conducts interdisciplinary study in the fields of Stereochemistry and Blood serum through his works.
Specifically, his work in Ruthenium is concerned with the study of Osmium. The study incorporates disciplines such as Iodide, Cyclopentadienyl complex, Mechanism of action, Glutathione and Adduct in addition to Ligand. His Cyclopentadienyl complex research is multidisciplinary, incorporating elements of Chelation, Substituent, Transfer hydrogenation and Structural isomer.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Organometallic chemistry, biology and medicine: ruthenium arene anticancer complexes
Yaw Kai Yan;Michael Melchart;Abraha Habtemariam;Peter J. Sadler.
Chemical Communications (2005)
Structure-activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands
Abraha Habtemariam;Michael Melchart;Rafael Fernandez;Simon Parsons.
Journal of Medicinal Chemistry (2006)
Controlling ligand substitution reactions of organometallic complexes: tuning cancer cell cytotoxicity.
F Y Wang;A Habtemariam;E P L van der Geer;R Fernandez.
Proceedings of the National Academy of Sciences of the United States of America (2005)
Organometallic Half-Sandwich Iridium Anticancer Complexes
Zhe Liu;Abraha Habtemariam;Ana M. Pizarro;Sally A. Fletcher.
Journal of Medicinal Chemistry (2011)
Catalytic organometallic anticancer complexes
Sarah J. Dougan;Abraha Habtemariam;Sarah E. McHale;Simon Parsons.
Proceedings of the National Academy of Sciences of the United States of America (2008)
Tuning the Reactivity of Osmium(II) and Ruthenium(II) Arene Complexes under Physiological Conditions
Anna F A Peacock;Abraha Habtemariam;Rafael Fernández;Victoria Walland.
Journal of the American Chemical Society (2006)
The Potent Oxidant Anticancer Activity of Organoiridium Catalysts
Zhe Liu;Isolda Romero-Canelón;Bushra Qamar;Jessica M. Hearn.
Angewandte Chemie (2014)
Transfer hydrogenation catalysis in cells as a new approach to anticancer drug design
Joan J. Soldevila-Barreda;Isolda Romero-Canelón;Abraha Habtemariam;Peter J. Sadler.
Nature Communications (2015)
Use of chelating ligands to tune the reactive site of half-sandwich ruthenium(II)-arene anticancer complexes.
Rafael Fernández;Michael Melchart;Abraha Habtemariam;Simon Parsons.
Chemistry: A European Journal (2004)
Competition between glutathione and guanine for a ruthenium(II) arene anticancer complex : detection of a sulfenato intermediate
Fuyi Wang;Jingjing Xu;Abraha Habtemariam;Juraj Bella.
Journal of the American Chemical Society (2005)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
University of Warwick
University of Warwick
University of Edinburgh
Czech Academy of Sciences
University of Warwick
Czech Academy of Sciences
University of Warwick
Sun Yat-sen University
Macquarie University
University of Santiago de Compostela
Polytechnic University of Milan
Carnegie Mellon University
Microsoft (United States)
Oklahoma State University
Texas State University
Duke University
Oslo University Hospital
University of Aberdeen
California Institute of Technology
Ludwig-Maximilians-Universität München
Shinshu University
KU Leuven
University of Bern
University of Delaware
Kyoto University
University of Tokyo